Revolution Financial Statements From 2010 to 2026

RVMD Stock  USD 118.81  1.28  1.09%   
Revolution Medicines' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Revolution Medicines' valuation are provided below:
Gross Profit
-880.5 M
Market Capitalization
23 B
Enterprise Value Revenue
8.4 K
Revenue
742 K
Earnings Share
(5.19)
There are over one hundred nineteen available trending fundamental ratios for Revolution Medicines, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Revolution Medicines' recent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 6.9 B. The current year's Enterprise Value is expected to grow to about 6.5 B

Revolution Medicines Total Revenue

11.58 Million

Check Revolution Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revolution Medicines' main balance sheet or income statement drivers, such as Net Interest Income of 104.9 M, Interest Income of 104.9 M or Depreciation And Amortization of 7 M, as well as many indicators such as Price To Sales Ratio of 265, Dividend Yield of 0.0 or PTB Ratio of 3.54. Revolution financial statements analysis is a perfect complement when working with Revolution Medicines Valuation or Volatility modules.
  
Build AI portfolio with Revolution Stock
Check out the analysis of Revolution Medicines Correlation against competitors.
For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.

Revolution Medicines Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.1 B2.9 B781.2 M
Slightly volatile
Other Current Liabilities116.7 M111.1 M31.3 M
Slightly volatile
Total Current Liabilities197.9 M188.5 M58.7 M
Slightly volatile
Total Stockholder Equity2.7 B2.6 B675.3 M
Slightly volatile
Other Liabilities6.3 M6.6 M9.3 M
Pretty Stable
Property Plant And Equipment Net171.3 M163.1 M47.9 M
Slightly volatile
Accounts Payable65.7 M62.6 M19.8 M
Slightly volatile
Cash655.7 M624.5 M179.6 M
Slightly volatile
Non Current Assets Total138 M265.3 M85.1 M
Slightly volatile
Non Currrent Assets Other21.2 M20.2 M4.9 M
Slightly volatile
Other Assets1.091.15877.4 K
Pretty Stable
Cash And Short Term Investments2.8 B2.6 B674.5 M
Slightly volatile
Common Stock Shares Outstanding202.5 M192.9 M74.2 M
Slightly volatile
Liabilities And Stockholders Equity3.1 B2.9 B781.2 M
Slightly volatile
Non Current Liabilities Total156 M148.6 M47.2 M
Slightly volatile
Capital Surpluse1.3 B1.2 B438.7 M
Slightly volatile
Other Current Assets46.3 M44.1 M10.9 M
Slightly volatile
Other Stockholder Equity4.8 B4.6 B1.2 B
Slightly volatile
Total Liabilities353.9 M337.1 M105.9 M
Slightly volatile
Property Plant And Equipment Gross197.6 M188.2 M54.7 M
Slightly volatile
Total Current Assets2.8 B2.7 B687.8 M
Slightly volatile
Non Current Liabilities Other572.9 K603 K2.6 M
Pretty Stable
Net Working Capital2.6 B2.5 B630.8 M
Slightly volatile
Common Stock21.7 K20.7 KK
Slightly volatile
Property Plant Equipment89 M84.8 M31.2 M
Slightly volatile
Short and Long Term Debt Total164 M156.2 M41.8 M
Slightly volatile
Common Stock Total Equity6.6 K9.2 K5.2 K
Slightly volatile
Long Term Debt Total136.8 K153.9 K168 K
Slightly volatile
Capital Stock15.4 K16.2 K18 M
Very volatile
Short Term Debt15.5 M14.8 MM
Slightly volatile
Intangible Assets47.9 M51 M60.2 M
Slightly volatile
Short Term Investments2.1 BB551.1 M
Slightly volatile
Deferred Long Term Liabilities513 K540 K1.9 M
Slightly volatile

Revolution Medicines Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income104.9 M99.9 M20.8 M
Slightly volatile
Interest Income104.9 M99.9 M20.9 M
Slightly volatile
Depreciation And AmortizationM13.6 M4.7 M
Slightly volatile
Interest Expense331 K348.4 K710 K
Pretty Stable
Selling General Administrative117.5 M111.9 M32.5 M
Slightly volatile
Other Operating Expenses832.6 M793 M229 M
Slightly volatile
Research Development715.1 M681.1 M196.4 M
Slightly volatile
Cost Of Revenue715.1 M681.1 M195.7 M
Slightly volatile
Total Operating Expenses832.6 M793 M216.4 M
Slightly volatile
Reconciled DepreciationM13.6 M4.7 M
Slightly volatile
Non Operating Income Net Other1.3 M836.1 K1.8 M
Slightly volatile
Selling And Marketing Expenses2.6 M2.9 M3.1 M
Slightly volatile

Revolution Medicines Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation95.6 M91.1 M23.2 M
Slightly volatile
Begin Period Cash Flow840.6 M800.6 M171.5 M
Slightly volatile
Other Cashflows From Financing Activities310.3 K326.6 K80.5 M
Pretty Stable
DepreciationM13.6 M4.7 M
Slightly volatile
Capital ExpendituresM11.9 M4.3 M
Slightly volatile
Total Cash From Financing Activities1.2 B1.1 B341.7 M
Slightly volatile
End Period Cash Flow655.7 M624.5 M179.8 M
Slightly volatile
Change To Netincome34 M32.4 M11.2 M
Slightly volatile
Issuance Of Capital StockB973.3 M287.2 M
Slightly volatile
Change Receivables396.7 K417.6 K1.7 M
Slightly volatile
Cash And Cash Equivalents Changes4.2 M4.4 M58.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio265252103
Slightly volatile
PTB Ratio3.543.72112
Slightly volatile
Days Sales Outstanding75.4645.4595.8543
Slightly volatile
Book Value Per Share12.7612.155.0754
Slightly volatile
Stock Based Compensation To Revenue5.044.81.3381
Slightly volatile
Capex To Depreciation0.981.01.0807
Slightly volatile
PB Ratio3.543.72112
Slightly volatile
EV To Sales21520588.6994
Slightly volatile
Payables Turnover6.347.147.7891
Slightly volatile
Sales General And Administrative To Revenue6.175.881.8965
Slightly volatile
Research And Ddevelopement To Revenue34.5332.8910.6898
Slightly volatile
Capex To Revenue0.630.60.2283
Slightly volatile
Cash Per Share12.912.285.0007
Slightly volatile
Days Payables Outstanding36.8241.4345.2207
Slightly volatile
Intangibles To Total Assets0.03040.0320.288
Slightly volatile
Net Debt To EBITDA0.770.690.5398
Slightly volatile
Current Ratio6.4512.785.4349
Slightly volatile
Tangible Book Value Per Share12.3611.774.5376
Slightly volatile
Receivables Turnover4.938.314.7964
Slightly volatile
Shareholders Equity Per Share12.7612.155.0754
Slightly volatile
Debt To Equity0.0510.0540.0335
Slightly volatile
Capex Per Share0.05530.06150.0568
Slightly volatile
Revenue Per Share0.110.120.4865
Slightly volatile
Interest Debt Per Share0.380.730.2903
Slightly volatile
Debt To Assets0.04310.04780.0282
Slightly volatile
Operating Cycle75.4645.4595.8543
Slightly volatile
Price Book Value Ratio3.543.72112
Slightly volatile
Days Of Payables Outstanding36.8241.4345.2207
Slightly volatile
Ebt Per Ebit1.061.00.9866
Slightly volatile
Company Equity Multiplier1.711.32.2767
Slightly volatile
Total Debt To Capitalization0.04710.05090.0311
Slightly volatile
Debt Equity Ratio0.0510.0540.0335
Slightly volatile
Quick Ratio6.4212.785.4204
Slightly volatile
Net Income Per E B T0.780.90.9308
Very volatile
Cash Ratio1.862.981.8723
Slightly volatile
Days Of Sales Outstanding75.4645.4595.8543
Slightly volatile
Price To Book Ratio3.543.72112
Slightly volatile
Fixed Asset Turnover0.130.11582.1163
Slightly volatile
Debt Ratio0.04310.04780.0282
Slightly volatile
Price Sales Ratio265252103
Slightly volatile
Asset Turnover0.00610.00650.0867
Slightly volatile
Price Fair Value3.543.72112
Slightly volatile

Revolution Medicines Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.9 B6.6 B2.4 B
Slightly volatile
Enterprise Value6.5 B6.2 B2.3 B
Slightly volatile

Revolution Fundamental Market Drivers

Revolution Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Revolution Medicines Financial Statements

Revolution Medicines stakeholders use historical fundamental indicators, such as Revolution Medicines' revenue or net income, to determine how well the company is positioned to perform in the future. Although Revolution Medicines investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revolution Medicines' assets and liabilities are reflected in the revenues and expenses on Revolution Medicines' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revolution Medicines. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-49.1 M-46.6 M
Cost Of Revenue681.1 M715.1 M
Stock Based Compensation To Revenue 4.80  5.04 
Sales General And Administrative To Revenue 5.88  6.17 
Research And Ddevelopement To Revenue 32.89  34.53 
Capex To Revenue 0.60  0.63 
Revenue Per Share 0.12  0.11 
Ebit Per Revenue(48.38)(45.96)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:
Check out the analysis of Revolution Medicines Correlation against competitors.
For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.19)
Revenue Per Share
0.005
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.32)
Return On Equity
(0.61)
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.